Timber Pharmaceuticals Inc. Announces 50% Enrollment in Phase 2b

Timber Pharmaceuticals Inc. announced that 50% of patients in the Phase 2b CONTROL study evaluating TMB-001 patients have been randomized. The company is a biopharmaceutical company that focuses on developing and commercializing treatments for rare and orphan dermatologic diseases. The final tranche of the $1.5 million grant has been awarded to the U.S. Food and Drug Administration.

Alan Mendelsohn, Chief Medical Officer of Timber Pharmaceuticals Inc., said, “There are many rare dermatologic diseases that do not have any approved therapies and we are committed to advancing research focused on novel topical treatments that may enable targeted delivery to the epidermis and dermis while minimizing systemic absorption.”

Alan also said that the people living with CI face many challenges in their everyday life, physically and psychologically. He said that their enrolment in the CONTROL study was a complete success. It is a testament to the tremendous need for new treatment options. He is also grateful to the patients participating and organizations like Foundation for Ichthyosis & Related Skin Types (FIRST) to raise awareness.

CI is a rare genetic keratinization disorder that leads to scaling, thickening, and dry skin. CI patients have limited motion, inability to sweat normally, chronic itching, and impaired eyesight or hearing. They also have a risk of secondary infections. Moderate to severe CI subtypes affects almost 80,000 people in the United States and more than 1.5 million people globally. The severe subtypes can also include X-linked ichthyosis and lamellar ichthyosis.

Dr. Mendelson hopes that isotretinoin’s formulation into a proprietary topical might allow up to 90% of body surface without eliciting the side effects.